BURNABY, British Columbia, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific…
Company CEO to discuss development at 1pm EST on 15th November 2023, at the Sidoti Virtual Investor Conference Loughborough, UK,…
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the…
BRISBANE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage…
Phase 2 MONTPARK trial expected to begin recruiting patients in Q1 2024SAINT LAURENT, Quebec, Nov. 14, 2023 (GLOBE NEWSWIRE) --…
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,…
Funding will support development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and other autoimmune conditionsParticipating investors include…
Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce…
Best Response to TCR-T Best Response to TCR-T TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of…
Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors Received approval by the Human…